Cargando…
Correction: Performance of next-generation sequencing on small tumor specimens and/or low tumor content samples using a commercially available platform
Autores principales: | Morris, Scott M., Subramanian, Janakiraman, Gel, Esma S., Runger, George C., Thompson, Eric J., Mallery, David W., Weiss, Glen J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023181/ https://www.ncbi.nlm.nih.gov/pubmed/29953541 http://dx.doi.org/10.1371/journal.pone.0200224 |
Ejemplares similares
-
Performance of next-generation sequencing on small tumor specimens and/or low tumor content samples using a commercially available platform
por: Morris, Scott, et al.
Publicado: (2018) -
Evaluation and comparison of two commercially available targeted next-generation sequencing platforms to assist oncology decision making
por: Weiss, Glen J, et al.
Publicado: (2015) -
Disparity in cholecalciferol content of commercial preparations available in India
por: Khadgawat, Rajesh, et al.
Publicado: (2013) -
Reactive lysine content in commercially available pet foods
por: van Rooijen, Charlotte, et al.
Publicado: (2014) -
FLUORIDE CONTENT OF UHT MILKS COMMERCIALLY AVAILABLE IN BAURU, BRAZIL
por: Buzalaf, Marília Afonso Rabelo, et al.
Publicado: (2006)